ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

XENE Xenon Pharmaceuticals Inc

43.00
0.00 (0.00%)
Pre Market
Last Updated: 09:09:47
Delayed by 15 minutes
Share Name Share Symbol Market Type
Xenon Pharmaceuticals Inc NASDAQ:XENE NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 43.00 17.20 68.37 0 09:09:47

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Third Quarter 2022 Financial Results and Provide Corporate Update

01/11/2022 8:01pm

GlobeNewswire Inc.


Xenon Pharmaceuticals (NASDAQ:XENE)
Historical Stock Chart


From May 2022 to May 2024

Click Here for more Xenon Pharmaceuticals Charts.

Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its third quarter 2022 financial and operating results after the close of U.S. financial markets on Tuesday, November 8, 2022.

Conference Call/Webcast Information:
  
Date:Tuesday, November 8, 2022
  
Time: 4:30 pm Eastern Time (1:30 pm Pacific Time)
  
Listen-Only Audio Webcast:https://edge.media-server.com/mmc/p/s4tct434
  
Live Call Participant:Registration Link

To participate in the live call, please register using the following link (also noted above) to receive dial-in details and a unique PIN code: Register and receive dial-in details. The audio webcast will also be broadcast live on the “Investors” section of Xenon's website at investor.xenon-pharma.com and posted for replay following the event. The above-listed dates and times are subject to change.

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.

“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

Investor/Media Contact:Jodi RegtsXenon Pharmaceuticals Inc.Phone: 604.484.3353Email: investors@xenon-pharma.com

1 Year Xenon Pharmaceuticals Chart

1 Year Xenon Pharmaceuticals Chart

1 Month Xenon Pharmaceuticals Chart

1 Month Xenon Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock